[The early results of pulmonary autograft mitral valve replacement (Ross Ⅱ) in infants]

M H Zou1, L Ma1, S C Yang1

  • 1Department of Cardiovascular Surgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.

Insights

Pulmonary autograft mitral valve replacement offers a feasible surgical option for infants with severe congenital mitral valve issues. Early results show improved clinical symptoms and satisfactory weight gain in survivors, despite one early death.

Area of Science:

  • Cardiovascular Surgery
  • Pediatric Cardiology
  • Congenital Heart Disease

Background:

  • Infants with intractable congenital mitral valve lesions often require complex surgical interventions.
  • The Ross II procedure, utilizing a pulmonary autograft for mitral valve replacement, presents a potential solution.

Purpose of the Study:

  • To evaluate the early outcomes of pulmonary autograft mitral valve replacement in infants.
  • To assess the feasibility and effectiveness of this procedure for congenital mitral valve disease.

Main Methods:

  • Six infants (50 days to 1 year old) with severe mitral valve insufficiency underwent pulmonary autograft mitral valve replacement.
  • A "top-hat" configuration using pericardium was employed for the autograft, with bovine jugular conduits for right ventricular outflow tract reconstruction.

Main Results:

  • One early death occurred. Five survivors showed improved clinical symptoms and satisfactory weight gain.
  • Echocardiography revealed acceptable flow velocities and gradients across the reconstructed mitral valve, with mostly normal cardiac dimensions and function in four patients.

Conclusions:

  • Pulmonary autograft mitral valve replacement is a potentially feasible and effective surgical strategy for infants with complex congenital mitral valve disease.
  • Early results suggest favorable outcomes, though long-term monitoring is essential.